Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1980 2
1981 3
1983 2
1984 1
1985 2
1987 2
1988 3
1992 1
1994 1
1996 1
2006 3
2007 2
2008 7
2009 11
2010 14
2011 28
2012 35
2013 57
2014 74
2015 69
2016 77
2017 78
2018 68
2019 52
2020 39
2021 45
2022 42
2023 13
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 21347804

588 results

Results by year

Filters applied: . Clear all
Page 1
Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study.
Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, Takeuchi T, Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N. Nishimoto N, et al. Mod Rheumatol. 2014 Jan;24(1):26-32. doi: 10.3109/14397595.2013.854080. Mod Rheumatol. 2014. PMID: 24261755
Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
Tanaka Y, Takeuchi T, Amano K, Saito K, Hanami K, Nawata M, Fukuyo S, Kameda H, Kaneko Y, Kurasawa T, Nagasawa H, Hoshi D, Sato E, Yamanaka H. Tanaka Y, et al. Mod Rheumatol. 2014 May;24(3):399-404. doi: 10.3109/14397595.2013.843757. Epub 2013 Nov 5. Mod Rheumatol. 2014. PMID: 24252045
Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, Schleypen J. Stubenrauch K, et al. Clin Ther. 2010 Aug;32(9):1597-609. doi: 10.1016/j.clinthera.2010.07.021. Clin Ther. 2010. PMID: 20974317
588 results